Literature DB >> 26999572

Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.

Francesco Cavazzini1, Enrico Lista1, Francesca Maria Quaglia1, Luca Formigaro1, Maurizio Cavallari1, Sara Martinelli1, Gian Matteo Rigolin1, Robin Foà2, Antonio Cuneo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26999572     DOI： 10.3109/10428194.2016.1154955

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Authors:  Jon E Arnason; Jennifer R Brown
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient program.

Authors:  Georg Gelbenegger; Christian Schoergenhofer; Ulla Derhaschnig; Nina Buchtele; Christian Sillaber; Michael Fillitz; Thomas M Schenk; Shirley D'Sa; Ronwyn Cartwright; James C Gilbert; Bernd Jilma; Ulrich Jaeger
Journal:  Blood Adv       Date:  2020-03-24

3.  [Ibrutinib treatment for 2 cases of relapsed/refractory autoimmune hemolytic anemia: a pilot study].

Authors:  L W Fang; H Pan; J Shi
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

Review 4.  Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs.

Authors:  Candida Vitale; Maria Chiara Montalbano; Chiara Salvetti; Elia Boccellato; Valentina Griggio; Mario Boccadoro; Marta Coscia
Journal:  Cancers (Basel)       Date:  2020-01-23       Impact factor: 6.639

Review 5.  The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia.

Authors:  Alessandro Noto; Ramona Cassin; Veronica Mattiello; Gianluigi Reda
Journal:  J Clin Med       Date:  2021-05-12       Impact factor: 4.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.